Oct 21 2026 09:13 PM EST

Oct 21 2026 09:00 AM EST

Regulatory clearance and diagnostic expansion lift MMTec and Myriad, while FMC slides on guidance cut

Shares of MMTec, Inc. (NASDAQ: MTC) jumped more than 45.4% and Myriad Genetics (NASDAQ: MYGN) rose 19.2% over the past five trading days, while FMC Corporation (NYSE: FMC) fell roughly 35% after a steep revision to its 2026 outlook.

MMTec: Nasdaq compliance removes delisting risk, short‑interest surge fuels squeeze speculation

The rally followed Nasdaq’s December 2025 decision that reinstated MMTec’s minimum‑bid‑price compliance, eliminating an imminent delisting catalyst. In the same period short interest climbed to 656.6 k shares (≈0.7% of float), a year‑to‑date increase of roughly 1,974%, pushing the days‑to‑cover metric to 37.2 days. FY 2025 revenue was modest at $808 k with a net loss of $56.1 million, but the balance sheet showed cash of $6.51 million and a current ratio of 12.5, indicating ample short‑term liquidity.

Myriad Genetics: Expanded Precise MRD test drives modest rebound amid ongoing headwinds

The 19.2% share‑price gain was triggered by the commercial rollout of the Precise MRD (molecular residual disease) assay in colorectal, renal and breast cancers. The test builds on earlier limited launches and aligns with industry momentum toward ctDNA‑based monitoring. Nevertheless, Myriad’s underlying financials remain pressured: Q2 2026 revenue fell 11% YoY to $190.7 million, gross margin slipped to 66.6%, and trailing‑12‑month net income was a loss of $230 million. Management cut its 2026 revenue guidance to $770–$790 million (down from $860–$880 million) and suspended EBITDA guidance, citing reimbursement friction in prenatal testing and pricing pressure across its legacy segments.

FMC: Guidance cut reflects soft crop‑protection demand and elevated inventory, prompting a steep share decline

FMC announced a revised Q3 2026 revenue range of $65 million–$125 million, down sharply from the prior $840 million–$900 million outlook (excluding India). Adjusted EBITDA is now projected as a loss of $510 million–$565 million, versus an earlier profit expectation of $120 million–$140 million. Full‑year revenue guidance was trimmed to $3.5 billion–$3.7 billion (consensus $3.7 billion) and FY 2026 EPS to $1.19–$1.49 (consensus $1.68). Management attributed the downgrade to one‑time charges of roughly $625 million–$675 million from price cuts in four countries and a U.S. pricing‑model overhaul aimed at clearing elevated channel inventory. The agricultural sector remains subdued as farmers curb planting and fertilizer use amid higher input costs and rising rates, while geopolitical disruptions in the Strait of Hormuz add supply‑chain risk.

Sector contrast: Diagnostics and storage gain focus as agro‑chemicals falter

The divergent moves underscore a broader sector split. In the diagnostics arena, Myriad’s product expansion illustrates continued investor interest in high‑margin, specialty assays despite reimbursement volatility. Similarly, Quantum Corp (NASDAQ: QMCO) reported its first positive adjusted EBITDA since 2025, driven by a 27% revenue jump to $78.0 million and aggressive debt reduction, reflecting robust demand for high‑density storage solutions in the video‑surveillance and AI‑generated‑data markets. By contrast, FMC’s exposure to cyclical crop‑protection inputs left it vulnerable to softening agricultural spending, inventory overhang, and commodity‑price pressure.

Overall, the five‑day performance differential highlights how investors reward companies that clear regulatory hurdles or broaden high‑margin product pipelines, while penalizing those confronting sector‑wide demand weakness and adverse guidance revisions. Future stock trajectories will hinge on MMTec’s ability to translate short‑interest dynamics into sustainable earnings, Myriad’s success in scaling the Precise MRD assay and resolving reimbursement disputes, and FMC’s execution of its strategic review and debt‑reduction plan amid a still‑soft agricultural backdrop.